PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PROTEASOME INHIBITOR OR IMMUNOMODULATORY DRUG FOR THE TREATMENT OF HEMATOLOGICAL CANCER - Patent 3522891

(19)

(11)

EP 3 522 891 A1

(12)

(43)	Date of publication:
	14.08.2019 Bulletin 2019/33

(21)	Application number: 17858740.8

(22)	Date of filing: 29.09.2017

(51)

International Patent Classification (IPC):

A61K 31/496^(2006.01)
A61K 31/69^(2006.01)
A61K 31/573^(2006.01)

A61K 31/416^(2006.01)
A61K 31/56^(2006.01)

(86)	International application number:
	PCT/KR2017/011015

(87)	International publication number:
	WO 2018/066946 (12.04.2018 Gazette 2018/15)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	MA MD

(30)

Priority:

04.10.2016 KR 20160127767

(71)	Applicant: Chong Kun Dang Pharmaceutical Corp.
	Seoul 03742 (KR)

(72)	Inventor:
	KIM, Soo Jin Yongin-si Gyeonggi-do 16995 (KR)

(74)	Representative: Bates, Philip Ian
	Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS London E1 8QS (GB)

(54)	PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PROTEASOME INHIBITOR OR IMMUNOMODULATORY DRUG FOR THE TREATMENT OF HEMATOLOGICAL CANCER